Antiepileptic drug shows promise for treatment of Parkinson's disease
This article has no abstract so we have provided the first paragraph of the full text.
Zonisamide is an antiepileptic drug with a long half-life, which has been widely prescribed in Japan. Following several preliminary trials indicating that zonisamide might improve the main symptoms of Parkinson's disease (PD), the Japan Zonisamide on PD Study Group carried out research to examine the efficacy, safety and tolerability of daily oral zonisamide in a cohort of patients with PD who were not responding well to levodopa.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
